These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19939207)

  • 1. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
    Tang W; Lu AY
    Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.
    Tang W
    Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):407-20. PubMed ID: 17539747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
    Zhou S; Chan E; Duan W; Huang M; Chen YZ
    Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of reactive drug metabolites in immune-mediated adverse drug reactions.
    Hess DA; Rieder MJ
    Ann Pharmacother; 1997 Nov; 31(11):1378-87. PubMed ID: 9391694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of metabolic activation in drug-induced hepatotoxicity.
    Park BK; Kitteringham NR; Maggs JL; Pirmohamed M; Williams DP
    Annu Rev Pharmacol Toxicol; 2005; 45():177-202. PubMed ID: 15822174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of new chemical entities with decreased potential for adverse drug reactions.
    Park KB; Dalton-Brown E; Hirst C; Williams DP
    Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical approaches to resolving reactive metabolite liabilities in early discovery.
    Dalvie D; Kalgutkar AS; Chen W
    Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive metabolites as a cause of hepatotoxicity.
    Prescott LF
    Int J Clin Pharmacol Res; 1983; 3(6):437-41. PubMed ID: 6381340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are chemically reactive metabolites responsible for adverse reactions to drugs?
    Williams DP; Kitteringham NR; Naisbitt DJ; Pirmohamed M; Smith DA; Park BK
    Curr Drug Metab; 2002 Aug; 3(4):351-66. PubMed ID: 12093355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.
    Bolleddula J; DeMent K; Driscoll JP; Worboys P; Brassil PJ; Bourdet DL
    Drug Metab Rev; 2014 Aug; 46(3):379-419. PubMed ID: 24909234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-cytochrome P450-mediated bioactivation and its toxicological relevance.
    Gan J; Ma S; Zhang D
    Drug Metab Rev; 2016 Nov; 48(4):473-501. PubMed ID: 27533622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity.
    Zhang A; Sun H; Wang P; Han Y; Wang X
    Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
    Giri S; Nieber K; Bader A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of drug toxicity and relevance to pharmaceutical development.
    Guengerich FP
    Drug Metab Pharmacokinet; 2011; 26(1):3-14. PubMed ID: 20978361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.
    Blomme EA; Yang Y; Waring JF
    Toxicol Lett; 2009 Apr; 186(1):22-31. PubMed ID: 18996174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.